Trellus Health, the Welsh-registered digital health company that raised £28.5m gross when it floated on AIM in May 2021, has filed a notice of intention to appoint administrators and told the market that no return is expected for shareholders.
Trellus Health plc, registered in Penarth, near Cardiff, was built on chronic disease research carried out at Mount Sinai in New York and co-founded by Professor Marla Dubinsky. Its product, Trellus Elevate, combines data analytics with resilience coaching for patients managing long-term conditions, and is sold in the United States through its operating subsidiary, Trellus Health Inc.
The company listed on London's junior market in May 2021, raising £28.5m gross in an oversubscribed placing brokered by N+1 Singer, with minor cross-listings in Germany and the United States. It never reached the revenue scale that float implied.
Trading in the shares was suspended on 8 May 2026 after the board appointed restructuring advisers and warned that its cash runway ran only to mid-June. At that point monthly cash burn had already been cut to an average of about $300,000 through cost reductions and renegotiated vendor terms, and a convertible loan note facility from Alumni Capital LLC remained available but was described as constrained by market conditions. A co-founder had also extended an emergency loan to keep the business trading.
On 21 August the board filed the notice of intention, naming Paul Zalkin and Tom Parish of Quantuma Advisory as the intended administrators, with the appointment expected within five business days. The directors concluded that the company has insufficient funds to continue trading as a going concern.
"The board has resolved to take this action to protect the interests of creditors," the company said, adding that it does not anticipate any returns to shareholders.
The cap-table consequence is straightforward. Ordinary shareholders, including the institutions that took stock at the 2021 placing price and the founders whose equity was created at admission, sit behind creditors and are expected to be wiped out. Value, if any is recovered, will come from asset sales: the board is seeking buyers for the company's assets, including its shareholding in the US subsidiary.
The outcome is another data point on the health of AIM as a venue for early-revenue life sciences and digital health issuers, a cohort that has struggled to return to the market for follow-on capital since 2022. For Trellus, the practical question now is whether a trade buyer values the US operating business highly enough to leave anything behind for the listed parent.
Original source: BusinessCloud — https://businesscloud.co.uk/news/healthtech-trellus-to-crash-into-administration/
